CRNX news & sentiment — Crinetics Pharmaceuticals, Inc.

APR 27·Simply Wall StreetMed

A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance

Crinetics Pharmaceuticals (CRNX) has shown mixed recent share performance, with short-term declines contrasting with positive long-term returns. Simply Wall St's analysis suggests the company's fair value is $82.43 per share, significantly higher than its current trading price of $38.33, based on potential revenue growth from its clinical pipeline, particularly PALSONIFY. However, this optimistic outlook is subject to risks such as slower-than-expected uptake or further pipeline delays.

MAR 29·MSN

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

The article highlights Indivior, Liquidia, and Crinetics as top Quant pharma picks. It also mentions Merck's acquisition of Terns for $6.7 billion, indicating significant activity and investment in the pharmaceutical sector.

MAR 21·Intellectia AI

CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison

The article provides a financial overview of Crinetics Pharmaceuticals Inc (CRNX), detailing its revenue breakdown, profitability margins, and a comparison with competitors. It highlights CRNX's gross margin of 82.54% but notes negative operating and net margins, alongside a negative Return on Equity. The company's market capitalization is $3.72 billion, and it is benchmarked against industry leaders like INDV and GPCR.

$CRNX

A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Mixed Recent Share Performance

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B

CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison

News on $CRNX